3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
10
NET
8
Gastrointestinal
1
CNS
1
Conditions
Carcinoma, Hepatocellular
14
Colorectal Neoplasms
13
Stomach Neoplasms
12
Pancreatic Neoplasms
11
Liver Neoplasms
8
Neuroendocrine Tumors
7
Neoplasm Metastasis
6
Gastrointestinal Neoplasms
4
Esophageal Neoplasms
4
Colonic Neoplasms
4
Neoplasms
3
Digestive System Neoplasms
3
Gastrointestinal Stromal Tumors
2
Gastro-enteropancreatic neuroendocrine tumor
2
Gallbladder Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Breast Neoplasms
2
Adenocarcinoma Of Esophagus
2
Adenocarcinoma
2
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Tongue Neoplasms
1
Thrombocytosis
1
Stomach Diseases
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Salivary Gland Neoplasms
1
Interventions
lanreotide
2
Temozolomide
2
Capecitabine
2
zimberelimab
1
veliparib
1
pembrolizumab
1
ganitumab
1
conatumumab
1
arginyllysine
1
Sunitinib
1
Rose Bengal
1
Quality of Life
1
Patient Reported Outcome Measures
1
Octreotide
1
Molecular Diagnostic Techniques
1
Immunotherapy
1
Everolimus
1
Drug Therapy
1
Biological Therapy
1
Bevacizumab
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoid Tumor
×
Everolimus
×
Gastrointestinal
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled